Novo Nordisk (NYSE:NVO) has drawn fresh attention after recent share price moves, with the stock closing at US$45.97. Investors are weighing this level against its longer term returns and current fundamentals.

That jump in Novo Nordisk’s share price over the last session sits against a weaker backdrop, with the 7 day share price return down 10.93% and the year to date share price return down 12.25%. The 1 year total shareholder return is down 2.61% and the 3 year total shareholder return has declined 46.63%, pointing to fading momentum over a longer horizon.

If Novo Nordisk is on your radar, this can be a good moment to broaden your watchlist and check out 42 healthcare AI stocks

After that sharp pullback and the longer slump in total returns, Novo Nordisk now sits at a very different entry point for fresh capital. Do the current fundamentals still justify taking the risk at this price?

Most Popular Narrative: 55.4% Undervalued

The most followed valuation narrative on Novo Nordisk currently anchors fair value at $102.97 per share, compared with the recent close at $45.97. That gap has caught the eye of investors trying to reconcile weak recent returns with a much stronger long term story.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

According to MCOInvestors, this valuation hinges on a powerful mix of compounding revenue, firm profit margins and a future earnings multiple more often linked with faster growing sectors. Want to see which assumptions on GLP-1 adoption, profitability and future pricing power sit underneath that headline fair value, and how they connect back to today’s $45.97 share price.

Result: Fair Value of $102.97 (UNDERVALUED)

However, Novo Nordisk’s narrative could be knocked off course if trial results disappoint, or if regulators delay or deny key GLP-1 and adolescent approvals.

Next Steps

If this Novo Nordisk story appears finely balanced between risk and reward, consider acting promptly, reviewing the data independently and assessing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus, do not stop here. Broaden your opportunity set with fresh stock ideas that match clear, disciplined criteria.

• Target income potential by reviewing dependable payers in the 9 dividend fortresses.
• Hunt for quality at a reasonable entry point through the 50 high quality undervalued stocks.
• Prioritise resilience by focusing on companies in the 77 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.